Ronald Asbury Andrews - Net Worth and Insider Trading
Ronald Asbury Andrews Net Worth
The estimated net worth of Ronald Asbury Andrews is at least $118,590 dollars as of 2023-04-01. Ronald Asbury Andrews is the President & CEO of OncoCyte Corp and owns about 333,212 shares of OncoCyte Corp (OCX) stock worth over $118,090. Ronald Asbury Andrews is also the President, Medical Sciences of aTyr Pharma Inc and owns about 238 shares of aTyr Pharma Inc (LIFE) stock worth over $500. Details can be seen in Ronald Asbury Andrews's Latest Holdings Summary section.
Transaction Summary of Ronald Asbury Andrews
Ronald Asbury Andrews Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ronald Asbury Andrews owns 3 companies in total, including OncoCyte Corp (OCX) , Oxford Immunotec Global PLC (OXFD) , and Precipio Inc (PRPO) .
Click here to see the complete history of Ronald Asbury Andrews’s form 4 insider trades.
Insider Ownership Summary of Ronald Asbury Andrews
|Ticker||Comapny||Transaction Date||Type of Owner|
|OXFD||Oxford Immunotec Global PLC||2020-06-24||director|
Ronald Asbury Andrews Latest Holdings Summary
Ronald Asbury Andrews currently owns a total of 2 stocks. Among these stocks, Ronald Asbury Andrews owns 333,212 shares of OncoCyte Corp (OCX) as of August 16, 2022, with a value of $118,090 and a weighting of 99.58%. Ronald Asbury Andrews also owns 238 shares of aTyr Pharma Inc (LIFE) as of April 27, 2012, with a value of $500 and a weighting of 0.42%.
Latest Holdings of Ronald Asbury Andrews
|Ticker||Comapny||Latest Transaction Date||Shares Owned||Current Price ($)||Current Value ($)|
|LIFE||aTyr Pharma Inc||2012-04-27||238||2.10||500|
Holding Weightings of Ronald Asbury Andrews
Ronald Asbury Andrews Form 4 Trading Tracker
According to the SEC Form 4 filings, Ronald Asbury Andrews has made a total of 6 transactions in OncoCyte Corp (OCX) over the past 5 years, including 6 buys and 0 sells. The most-recent trade in OncoCyte Corp is the acquisition of 40,000 shares on August 16, 2022, which cost Ronald Asbury Andrews around $38,400.
According to the SEC Form 4 filings, Ronald Asbury Andrews has made a total of 0 transactions in aTyr Pharma Inc (LIFE) over the past 5 years. The most-recent trade in aTyr Pharma Inc is the acquisition of 238 shares on April 27, 2012, which cost Ronald Asbury Andrews around $154,812.
Insider Trading History of Ronald Asbury Andrews
Ronald Asbury Andrews Trading Performance
GuruFocus tracks the stock performance after each of Ronald Asbury Andrews's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ronald Asbury Andrews is -21.03%. GuruFocus also compares Ronald Asbury Andrews's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ronald Asbury Andrews within 3 months outperforms 2 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ronald Asbury Andrews's insider trading performs compared to the benchmark.
Performance of Ronald Asbury Andrews
Average Relative Return
|1 Month||3 Months||6 Months||1 Year||2 Years||3 Years|
|Relative Return to S&P 500(%)||-7.07||-25.35||-4.06||27.38||-56.01||-64.22|
Ronald Asbury Andrews Ownership Network
Ownership Network List of Ronald Asbury Andrews
Ownership Network Relation of Ronald Asbury Andrews
Ronald Asbury Andrews Owned Company Details
What does OncoCyte Corp do?
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Who are the key executives at OncoCyte Corp?
Ronald Asbury Andrews is the director of OncoCyte Corp. Other key executives at OncoCyte Corp include Interim CEO Josh Riggs , Controller & PAO James Yang Liu , and SVP & Finance & and Interim CFO Anish M. John .
OncoCyte Corp (OCX) Insider Trades Summary
Over the past 18 months, Ronald Asbury Andrews made 2 insider transaction in OncoCyte Corp (OCX) with a net purchase of 90,000. Other recent insider transactions involving OncoCyte Corp (OCX) include a net purchase of 11,964,028 shares made by Pura Vida Investments, Llc , a net purchase of 415,000 shares made by Andrew Arno , and a net purchase of 100,000 shares made by John Peter Gutfreund .
In summary, during the past 3 months, insiders sold 0 shares of OncoCyte Corp (OCX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 107,514 shares of OncoCyte Corp (OCX) were sold and 18,844,166 shares were bought by its insiders, resulting in a net purchase of 18,736,652 shares.
OncoCyte Corp (OCX)'s detailed insider trading history can be found in Insider Trading Tracker table.
OncoCyte Corp Insider Transactions
Ronald Asbury Andrews Mailing Address
Above is the net worth, insider trading, and ownership report for Ronald Asbury Andrews. You might contact Ronald Asbury Andrews via mailing address: 5791 Van Allen Way, Carlsbad Ca 92008.